Glecirasib is under clinical development by Jacobio Pharmaceuticals Group and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II drugs for Gastric Cancer have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Glecirasib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Glecirasib overview

Glecirasib (JAB-21000) is under development for the treatment of colorectal cancer (CRC), STK11 mutated non-small cell lung cancer (NSCLC), pancreatic cancer, pancreatic ductal adenocarcinoma, biliary tract tumors, gastric cancer, appendix cancer and other solid tumors. The drug candidate acts by targeting KRAS G12C. It is developed based on allosteric inhibitor discovery platform. It is administered through oral route in the form of tablet.

Jacobio Pharmaceuticals Group overview

Jacobio Pharmaceuticals Group (Jacobio Pharma) discovers and develops monotherapies to treat cancer. The company is investigating JAB-3068 program for the treatment of solid tumors, esophageal squamous cell carcinoma (ESCC), head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); JAB-3312 drug against pancreatic cancer and KRAS mutation in colorectal cancer, osimertinib progressed and KRAS G12C mutation in NSCLC. It is also evaluating JAB-8263 drug to treat solid tumors, myelofibrosis and acute myeloid leukemia (AML). Jacobio Pharma works in partnership with biotechnology and pharmaceutical companies. The company has its operations locations in Beijing and Shanghai, China and Massachusetts, the US. Jacobio Pharma is headquartered in Beijing, China.

For a complete picture of Glecirasib’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.